<DOC>
	<DOCNO>NCT01665950</DOCNO>
	<brief_summary>Primary Aim : To estimate antidepressant efficacy simvastatin versus placebo adjunct lithium , valproate , and/or atypical antipsychotic therapy among individual bipolar I disorder nonpsychotic major depressive episode . Hypothesis : Simvastatin superior placebo improvement depressive symptom assess Montgomery-Asberg Depression Rating Scale ( MADRS ) .</brief_summary>
	<brief_title>Simvastatin Augmentation Lithium Treatment Bipolar Depression</brief_title>
	<detailed_description>( see brief summary )</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Inclusion : Age 1865 write informed consent meet Diagnostic Statistical Manual IV ( DSMIV ) criterion ( Structured Clinical Interview DSMIV ( SCIDI/P ) ) bipolar I disorder , current episode depress MontgomeryAsberg Depression Scale ( MADRS ) score least 20 ( i.e. , moderate depression ) great 34 ( i.e. , severe depression ) screen baseline visit Young Mania Rating Scale ( YMRS ) score &lt; 12 screen baseline visit currently treat lithium preparation ( carbonate citrate ) stable dose least 4 wks level &gt; 0.4 &lt; 1.0 ; and/or valproate stable dose least 4 wks level &gt; 60 &lt; 110 ; and/or atypical antipsychotic stable dose least 4 week ( least minimum FDAlabeled dose ) . Exclusion : Psychotic feature current episode , assess YMRS item # 8 &gt; 6 felt study clinician require inpatient hospitalization adequate management 3 fail pharmacologic intervention current major depressive episode , exclusive primary mood stabilizer current substance use disorder nicotine , SCIDI/P pregnant woman woman child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) woman breastfeed serious suicide homicide risk , assess evaluate clinician unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease , base review medical history , physical examination , screen laboratory test patient take investigational psychotropic drug within last 30 day patient receive additional anticonvulsant , antipsychotic , antidepressant within 1 week prior study entry patient require continued treatment exclude medication ( see ) . Excluded medication : statin , could influence Wnt signal ; drug know interact simvastatin , include potent inhibitors/inducers CYP3A4 itraconazole , ketoconazole , posaconazole , erythromycin , clarithromycin , telithromycin , voriconazole , cyclosporine danazol ; gemfibrozil lipidlowering drug cause myopathy give alone ; amiodarone , ranolazine , verapamil , diltiazem , amlodipine ; niacin ; digoxin ; coumarin anticoagulant ; colchicine ; nefazodone ; protease inhibitor include ritonavir , indinavir , nelfinavir , saquinavir . Allowed : benzodiazepine sedativehypnotic agent dosage stable 2 week prior study entry ; thyroid estrogen replacement provide dosage stable 1 month ; antidepressant , antipsychotic , anticonvulsant provide dosage stable 1 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>